Open Access

Expression of eicosanoid receptors subtypes and eosinophilic inflammation: implication on chronic rhinosinusitis

Respiratory Research20067:75

DOI: 10.1186/1465-9921-7-75

Received: 24 October 2005

Accepted: 12 May 2006

Published: 12 May 2006

Abstract

Background

Eicosanoid receptors are G-protein-coupled receptors playing an important immunomodulatory role in airway diseases. However, there is little information on the expression of these receptors and their link with eosinophilic inflammation in paranasal sinus diseases. We aimed with this study to investigate the tissue expression of leukotrienes and prostaglandin E2 receptors in chronic rhinosinusitis patients and the link of this regulation with eosinophilic inflammation.

Methods

Samples were prepared from nasal tissue of patients with chronic rhinosinusitis without nasal polyps (CRS, n = 11), with nasal polyps (CRS-NP, n = 13) and healthy subjects (Controls, n = 6). mRNA expression of CysLT1, CysLT2, BLT1, BLT2, E-prostanoid receptors (EP1, EP2, EP3, EP4) and sol-IL-5Rα was determined by real-time PCR. Concentrations of PGE2, LTC4/D4/E4, LTB4 and sol-IL-5Rα were determined by ELISA and of ECP by ImmunoCap. Protein expression and tissue localization of eicosanoid receptors and activated eosinophils were evaluated by immunohistochemistry.

Results

CysLT1 mRNA expression was significantly increased in CRS-NP compared to CRS and controls, and CRS compared to controls, whereas CysLT2 mRNA was enhanced in both CRS groups without differences between them. Levels of both receptors correlated to the number of activated eosinophils, sol-IL-5Rα, ECP and LTC4/D4/E4 concentrations in the disease groups. PGE2 protein concentrations and prostanoid receptors EP1 and EP3 were down-regulated in the CRS-NP tissue vs. CRS and controls, whereas EP2 and EP4 expression was enhanced in CRS and CRS-NP patients vs. controls. No differences in BLT receptors were observed between patients and controls.

Conclusion

CyLTs receptors are up-regulated in nasal polyp tissue and their expression correlate with eosinophilic inflammation supporting previous results. Eicosanoid receptors mRNA pattern observed suggests that down-regulation of EP1 and EP3 in CRS-NP and up-regulation EP2 and EP4 in CRS and CRS-NP groups may have some role in the development of the diseases and their regulation may not be directly linked to eosinophil activation but involve post-transcriptional events mainly related to other inflammatory cell sources.

Background

The role of eicosanoids in the pathophysiology of chronic inflammatory airway diseases has been well documented; however, the key steps in the regulation leading to the production of these molecules remain unclear. Eicosanoid signalling pathway operates through lipid G-protein-coupled receptors (GPCRs) [1]. According to the International Union of Pharmacology (IUPHAR), eicosanoid receptors are classified in four main groups: the BLT receptors, with biological activities related to LTB4, the cysteinyl leukotrienes (cysLTs) receptors related family, the lipoxin (ALX) receptors and the prostanoid receptors class [1].

Interaction of cysteinyl leukotrienes receptors (CysLT1 and CysLT2) with theirs ligand LTC4, LTD4 and LTE4 play a disease-regulating role in chronic rhinosinusitis/nasal polyposis and particularly in the aspirin intolerance syndrome which is often correlated to these diseases. The biological actions of these molecules include endothelial cell adherence, myofibroblast proliferation, bronchoconstriction, vascular hyper-permeability, mucus secretion and chemokine production [2]. Immunohistochemical studies have revealed that the cysLTs receptors are expressed on eosinophils, mast cells, macrophages, neutrophils and vascular endothelial cells in the nasal mucosa [3]. Expression of these receptors has been also demonstrated in inflammatory cells in patients with seasonal allergic rhinitis [4]. In addition, in vitro studies involving cysLTs receptor antagonists have also demonstrated the crucial role of these molecules in the regulation of plasma extravasation and vascular endothelial growth factor synthesis [5]. These, are important events involved in the development of oedema formation in nasal polyps and in the pathogenesis of allergen-induced asthma. Of interest, a recent study performed in patients with chronic rhinosinusitis/aspirin intolerance showed that effects of cysteinyl leukotrienes in the nasal mucosa of these patients seems to occur mainly via interaction with CysLT1 on inflammatory leukocytes. However, effects of these eicosanoids on glands and epithelium may be mediated predominantly through CysLT2 [6].

Additionally, controversial results about LTB4 and BLT receptors have been reported in several studies. BLT1 is expressed primarily in leukocytes, human BLT2 is present in most human tissues [7, 8]. In human peripheral blood leukocytes, neutrophils and eosinophils express significant amounts of both BLT1 and BLT2, whereas mononuclear cells express BLT2 but minimal BLT1 [8]. Expression of BLT receptors can be up-regulated during inflammation; however, the specific inflammatory stimuli responsible for their induction have not yet been fully characterized. In human airways, BLT receptor-LTB4 mediated action play a crucial role in host defence by regulating processes like recruitment, activation and survival of cells during inflammation [911]. However, until now, no clear mechanism regulating the synthesis of these molecules in airway has been yet demonstrated.

Finally, the role of prostaglandins in physiology and immune system is determined by multiple factors such as cellular context, receptor expression profile, receptor-ligand affinity and differential regulation of signal transduction pathways [12]. The prostanoid receptor subfamily comprises eight members: the prostaglandin D (DP) receptor, the prostaglandin E2 receptors (EP1, EP2, EP3 and EP4), the prostaglandin F receptor (FP), the prostaglandin I receptor (IP), the tromboxane A receptor (TP), and a ninth prostaglandin receptor identified recently, the chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2) [12].

In airways, PGE2 may induce bronchodilation and airway relaxation by acting via EP2 receptor [13, 14]. Basal expression of EP2 and EP4 receptors is increased on bronchial inflammatory cells from asthmatic patients and may be altered in vitro on eosinophils in response to inflammatory stimuli, suggesting the immunomodulatory role of these receptors in asthma, [15]. More recently, a study comparing EP receptor expression in nasal biopsies from aspirin intolerant and tolerant patients showed an up-regulation of EP1 and EP2 in structural cells from aspirin intolerant subjects [15]. However, in the same study the number of inflammatory cells expressing EP2 but not EP1, EP3 or EP4 receptors was significantly up-regulated in the aspirin intolerant group [15].

Based on the previous studies, we hypothesize that eicosanoid receptor expression is altered in chronic rhinosinusitis patients with and without nasal polyposis in absence of aspirin intolerance and these changes may be related to eosinophilic inflammation.

Methods

Patients and clinical diagnosis

Samples from ethmoidal and maxillary sinuses were collected during functional endoscopic sinus surgery (FESS) procedures in the Department of Otorhinolaryngology at the Ghent University Hospital. Nasal tissues were obtained from 13 patients with chronic rhinosinusitis and nasal polyposis (CRS-NP) (10 males, 3 females, age range: 30–54 years) and 11 subjects with chronic rhinosinusitis without nasal polyposis CRS (8 males, 3 females, age range: 21–53 years) who were scheduled for sinus surgery in the department of Othorinolaryngology of the Ghent University Hospital. As control group (Controls), we included 6 subjects (4 males, 2 females, age range: 21–53 years), who underwent septal surgery and removal of parts of the inferior turbinate due to anatomical variations. These patients had any acute or chronic clinical, endoscopic or imaging signs of sinusitis or polyposis; and they did not show any history of atopic, or lower airway disease.

Diagnosis of CRS was based on the presence of typical symptoms (headache, nasal obstruction and discoloured nasal drainage) longer than 12 weeks and a positive CT-Scan showing swelling of the ethmoidal and maxillary mucosa and bilateral obstruction of the osteomeatal complex but without polyp formation, visible during nasal endoscopy or during surgery. Nasal polyposis was diagnosed based on symptoms history (nasal congestion, lost of smell, changes in sense of taste and persistent postnasal drainage), clinical examination, nasal endoscopy and paranasal sinuses CT-Scan, defined as presence of visible bilateral polyps growing from the middle meatus into the nasal cavities, and affecting the ethmoidal sinuses. In the CRS-NP group, three patients had asthma and in the CRS group, there was one patient with allergic rhinitis and one with asthma. Diagnosis of asthma was based on clinical history, typical symptoms and lung (pulmonary) function tests (Spirometry and Peak Expiratory Flow), following the Global initiative for asthma (GINA) guidelines. All patients have taken aspirin or other NSAIDs without manifesting any hypersensitive reaction.

The study was approved by the ethical committee of the Ghent University Hospital, and all patients gave informed consent before their participation. The use of any oral medication with possible impact on measurements of enzymes or mediators, including systemic glucocorticoids and anti-leukotrienes, was stopped in all subjects 4 weeks before surgery. The use of topical glucocorticoids was interrupted 2 weeks before surgery.

Real time PCR for eicosanoid receptors

Quantitative real time PCR was used to determine the mRNA levels of eicosanoid receptors. Nasal tissue (30 mg) was homogenized in Tri-reagent buffer (Sigma-Aldrich, MO, USA), 1 ml per 50–100 mg of tissue, in a chilled pestle mortar. Total RNA from homogenates was isolated using Tri-reagent Kit following the manufacturer's instructions (Sigma-Aldrich, MO, USA). cDNA was synthesized from 2 μg of total RNA using Oligo(dT)12–18, random hexamers and the Superscript RNase H-Reverse Transcriptase (Life Technologies, CA, USA), as described previously [16]. Amplification reactions were performed on an iCycler iQ Real-Time PCR Detection System (Bio-Rad laboratories, CA, USA) using specific primers (Table 1), designed with the Primer3 software [17]. PCR reactions contained 20 ng cDNA (total RNA equivalent) of unknown samples, 1X SYBR Green I Master mix (Bio-Rad laboratories, CA, USA) and 300 nM of primer pairs in a final volume of 25 μl. PCR protocol consisted of 1 cycle at 95°C for 10 minutes followed by 45 cycles at 95°C for 30 seconds and at 60°C for 1 minute. The expression of two housekeeping genes Beta actin (ACTB) and Hydroxymethyl-bilane synthase (HMBS) was used to normalize for transcription and amplification variations among samples. The relative number of molecules of each gene, expressed in relative expression units quantified per 20 ng of cDNA sample, was determined by the ΔCT value method as described previously [18].
Table 1

Primer sequences used for real time PCR amplification

Eicosanoid receptors

Forward primer (5'→ 3')

Reverse primer (5'→ 3')

Amplicon size

Genbank Accession number

EP1

GATGGTGGGCCAGCTTGTC

GCCACCAACACCAGCATTG

73 bp

NM_000955

EP2

GACCGCTTACCTGCAGCTGTAC

TGAAGTTGCAGGCGAGCA

73 bp

NM_000956

EP3

AAGGCCACGGCATCTCAGT

TGATCCCCATAAGCTGAATGG

76 bp

NM_000957

EP4

ACGCCGCCTACTCCTACATG

AGAGGACGGTGGCGAGAAT

63 bp

NM_000958

BLT1

CCTGAAAAGGTGCAGAAGC

AAAAAGGGAGCAGTGAGCAA

93 bp

NM_000752

BLT2

CTTCTCATCGGGCATCACAG

ATCCTTCTGGGCCTACAGGT

88 bp

NM_019839

CysLT1

TCCTTAGAATGCAGAAGTCCGTG

AAATATAGGAGAGGGTCAAAGCAA

80 bp

NM_006639

CysLT2

GCTGATCATTCGGGTTCTGT

GGTGATGATGATGGTGGTCA

91 bp

NM_020377

Eicosanoid levels

Concentration of cysteinyl leukotrienes C4/D4/E4 (LTC4/D4/E4), prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) were measured by Enzyme Linked Immunoassays (ELISAs) purchased from Oxford BioMedicals (Oxford, USA). Sample extraction procedures for protein removal and eicosanoid stabilization were performed according to the provider's instructions. Briefly, nasal or sinus tissues were first homogenized in ethanol (5 ml/g) for LTB4 and LTC4/D4/E4, and in 15% methanol/0.1 M sodium phosphate buffer, pH 7.5 for PGE2 measurements and then centrifuged for 5 minutes at 3,000 rpm at 4°C. Supernatants were diluted in water, pH 3.5 and following manufacturer's instructions (Oxford BioMedicals, Oxford, USA). The detection ranges for all assays were between 0.02–10 ng/ml. The sensitivity was of 0.2 ng/ml for all assays and the intra-and inter-assay coefficient of variation less than 10%.

Eosinophil inflammatory markers

Soluble IL-5Rα isoform was quantified using a real time PCR, as described previously [16]. Briefly, a standard curve was constructed from a plasmid containing the cDNA sequence for this receptor isoform. A fragment of this plasmid was amplified with specific primers, purified and used in equimolar 10-fold dilutions to generate a standard curve. Real time amplifications were performed in a 25 μl volume reaction containing 1X SYBR Green I Master mix (Bio-Rad laboratories, CA, USA), 300 nM of primer pairs and a set of primers specific for this hIL-5Rα isoform [16]. PCR protocol consisted of 1 cycle at 95°C for 10 minutes followed by 40 cycles at 95°C for 30 seconds and at 64°C for 1 minute. Each sample was tested in duplicate. The quantity of each amplicon was calculated from the values of the standard curve and normalized by the quantities obtained for beta actin (ACTB) and hydroxymethyl-bilane synthase (HMBS).

Soluble IL-5α receptor protein concentrations were measured by a research ELISA as described previously [19] with a sensitivity of 8 pg/ml. and an intra-and inter-assay coefficient of variation less than 10%. Quantification of Eosinophil Cationic Protein (ECP) was carried out, on supernatants obtained after nasal tissue homogenization, by the UniCAP system (Pharmacia & Upjohn, Sweden), with a detection limit of < 0.5 μg/L and a coefficient of variation less than 10%.

The number of activated eosinophils was determined by staining the eosinophil granulocyte (EG2) and semiquantitative scoring of positively stained cells on the different tissues. For that, frozen tissue sections were fixed in acetone for 10 minutes, washed in TBS buffer and incubated with (1:1000) mouse anti-human ECP/EPX monoclonal antibody (Pharmacia & Upjohn Uppsala, Sweden) for 1 hour. Then, the slides were incubated with (1:50) rabbit anti-mouse IgG for 10 minutes and developed with (1:100) alkaline phosphatase anti-alkaline phosphatase (Dako, Glostrup, Denmark) for 10 minutes at room temperature. Signal detection was performed using the New Fuchsin Substrate System, following the manufacture's instructions (Dako, Glostrup, Denmark). Semiquantitative scoring was performed by a pathologist, who was blinded for the clinical data, on a four-point scale adapted from an already validated system of semiquantitative evaluation. Zero represented the lowest and three the highest score. The analysis included all areas of the biopsies and a global score was given for each parameter.

Immunohistochemical staining for prostanoid and leukotriene receptors

Frozen tissue sections were fixed in acetone for 10 minutes at room temperature and washed in 1X TBS buffer. Endogenous peroxidase activity was blocked with 0.3 % hydrogen peroxidase (VWR International, Pennsylvania, USA) in PBS containing 0,001 % NaN3 for 20 minutes at room temperature. Sections were than washed for 10 minutes with 1X TBS and incubated with foetal bovine serum during 30 minutes. Sections were then incubated for 1 hour at room temperature with primary antibodies: rabbit IgG polyclonal Antibodies for EP1 receptor (1:250), EP2 receptor (1:250), EP3 receptor (1:200), EP4 receptor (1:250), CysLT1 (1:50) and CysLT2 (1:50), purchased by Cayman Chemicals (MI, USA). Signal was detected with LSAB+ kit (HRP Rabbit/Mouse/Goat) purchased from Dako, using the AEC+ High Sensitivity Substrate Chromogen Kit (Dako, Glostrup, Denmark). To control for unspecific binding of the primary antibodies used in the study, parallel stainings were performed omitting the primary antibody and by substituting it with an irrelevant antibody or non-immune sera of the same species (isotype), at the same concentration as the specific antibody (antisera).

Statistical data analysis

All data was analyzed using the MedCalc software version 6.0 (Mariakerke, Belgium). Results are presented in Box-and-Whisker plots, where the central box represent the values from the lower and upper interquartile range, and the middle line the median. Data comparison within different patient groups was performed using the Kruskal-Wallis test (H-test). The Wilcoxon test (or Mann-Whitney U test) for unpaired samples was applied to evaluate the statistical differences between two patient groups. Spearman's rank correlation analysis was performed to determine statistical significance of differences between two parameters in a classification group. P values equal or less than 0.05 was regarded as significant.

Results

mRNA expression of eicosanoid receptors by real time PCR

Expression of leukotrienes and prostanoid receptors analyzed by quantitative real time PCR showed an up-regulation of CysLT1 and CysLT2 receptors in CRS patients compared to controls, but only CysLT1 was significantly higher in CRS-NP in comparison to CRS patients as showed in Figure 1a. EP2 and EP4 mRNA was up-regulated in both CRS groups when compared with normal subjects (Figure 1b). In contrast, EP1 and EP3 expression was similar in controls and CRS patients but significantly down-regulated in the CRS-NP group (Figure 1b). Concentrations of BLT1 and BLT2 receptors were similar in the three groups of patients (data not shown).
Figure 1

mRNA levels of eicosanoid receptors in nasalmucosa. a) cysLTs receptors, b) prostanoid-E receptors. Controls: healthy subjects, CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyps. P: p value (unpaired Mann-Whitney U test).

Expression profile for the four EP and the two cysLTs receptors analyzed in each individual group of patients is illustrated in Figures 2 and 3. In the control group, expression of EP receptors did not show any differences. However, in the CRS and EP1 and EP3 receptors were down-expressed compared to EP2 and EP4 and this difference was more accentuated in the CRS-NP subjects. On the other hand CysLT1 and CysLT2 mRNA levels were similar in CRS and normal mucosa, however significantly higher concentrations of CysLT1 compared to CysLT2 were observed in the CRS-NP group.
Figure 2

Balance of mRNA levels of prostanoid E receptors innasal mucosa. Controls: healthy subjects, CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyps. P: p value (unpaired Mann-Whitney U test).

Figure 3

Balance of mRNA levels of cysteinyl leukotriene receptors in nasal mucosa. Controls: healthy subjects, CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyps. P: p value (unpaired Mann-Whitney U test

Eicosanoid levels and eosinophil inflammatory markers

Levels of eicosanoids and eosinophilic inflammatory markers are summarized in table 2. While concentrations of LTC4/D4/E4, were significantly higher in CRS-NP compared to CRS and controls, no differences were observed in LTB4 levels between the groups. PGE2 concentrations however, were similar in CRS and control (p > 0.10) but statistically lower in the nasal polyp tissue (p = 0.001). Real time PCR for sol-IL-5α R showed a significantly increase in CRS-NP subjects compared to CRS and in CRS compared to control subjects. Accordingly, sol-IL-5Rα protein was also statistically higher in the CRS-NP compared to CRS and in this group compared to control tissue. ECP was significantly increased in CRS compared to the control group (p < 0.05) and even more in CRS-NP (p < 0.02).
Table 2

Concentration of eicosanoids and eosinophilic inflammation markers in chronic rhinosinusitis patients

 

Controls

CRS

CRS-NP

Kruskall Wallis-test

Eicosanoids

LTC4/D4/E4 (ng/ml)

1.16 (IQR: 0.85–1.68)

3.34 (IQR: 2.70–5.35)

7.24 (IQR: 4.65–12.40)

P < 0.01 §

LTB4 (ng/ml)

25.25 (IQR: 8.26–63.91)

21.95 (IQR: 9.40–31.90)

19.44 (IQR: 12.80–29.71)

N.S

PGE2 (ng/ml)

180.63 (IQR: 101.44–258.86)

199.83 (IQR: 59.10–223.52)

55.00 (IQR: 40.59–67.87)

p = 0.02 ¶

Eosinophilic inflammation markers

ECP (μg/L)

602.51 (IQR: 309.90–894.30)

2090.00 (IQR: 1437.60–5442.40)

11880.00 (IQR: 1862.70–17920.74)

p < 0.01 §

Sol-IL-5Rα protein (ng/ml)

20.62 (IQR: 15.77–26.43)

50.95 (IQR: 28.62–67.78)

175.24 (IQR: 37.11–309.67)

P < 0.05 §

sol-IL-5Rα mRNA (pg/μl)

14757.50 (IQR: 12493.97–23015.35)

159065.30 (IQR: 45909.00–185796.90)

458449.55 (IQR: 267447.00–796387.30)

p = 0.02 §

EG2 positive cells

1,00 (IQR: 1,00–1,15)

1,05 (IQR: 1,00–1,40)

2,10 (IQR: 1,90–2,25)

p < 0.01 ¶

Results are expressed as median and interquartile ranges (IQR). §: p < 0.05 is due to differences between the three sample groups; (¶): p < 0.05 is due to differences in the levels of CRS-NP versus controls and CRS patients. N.S: No statistical differences, p value > 0.05. CRS: chronic rhinosinusitis, CRS-NP: chronic rhinosinusitis/nasal polyp, Controls: healthy subjects.

Immunohistochemistry results demonstrated a strong infiltration of inflammatory cells in the nasal polyp compared to the CRS and inferior turbinate tissues (data not shown) and the median score for EG2 positive cells was significantly higher in NP tissue compared to the control and CRS tissues as summarized in Table 2.

The Spearman's rank correlation analysis showed a strong correlation between both cysLTs receptors mRNA with sol-IL-5Rα protein concentrations (CysLT1: rho = 0,574, p = 0.01; CysLT2: rho = 0,523; p < 0.05), ECP (CysLT1: rho = 0,544, p = 0.02; CysLT2: rho = 0,413; p = 0.03) and the total number of activated eosinophils (CysLT1: rho = 0,546, p = 0.02; CysLT2: rho = 0,614; p = 0.03). No correlations were found between the levels of prostanoid receptors and eosinophilic inflammation markers.

Immunohistochemical staining for prostanoid and leukotriene receptors

Immunohistochemical staining for CysLT1 and CysLT2 receptors in the nasal tissue is represented in Figure 3. Immunoreactivity of both cysLTs receptors was observed in inflammatory cells in the lamina propria in both CRS groups. In addition, these receptors were expressed in the sub-epithelial layer of the nasal mucosa and to a lesser extend in the epithelium. Prostanoid-E receptors were mainly expressed in the epithelium and in mucosal glands (Figure 4). Immunoreactivity for EP2 and EP4 was higher in inflammatory cells compared to epithelium, contrary to EP1 and EP3 staining, which was localized mainly in epithelial and sub-epithelial regions and blood vessels.
Figure 4

Cysteinyl leukotriene receptors in chronicrhinosinusitis tissue. Representative photomicrography (original magnification 40 ×) of chronic rhinosinusitis/nasal polyp specimens immunostained for CysLT1 and CysLT2 receptors in inflammatory cells, epithelium, glands and blood vessels.

Discussion

Several studies have suggested changes in the eicosanoid regulation patterns as one of the factors involved in the pathophysiology of chronic rhinosinusitis and nasal polyposis; however, the effect of eicosanoids in the tissue, greatly dependents of the differential expression of the distinct subtypes of their receptors.

In this study, we confirmed that CysLT1 and CysLT2 receptors are up-regulated in chronic rhinosinusitis and nasal polyp patients. Interestingly, the balance of these receptors was similar in healthy and chronic rhinosinusitis subjects, in contrast to the nasal polyp group where expression of CysLT1 was significantly higher when compared to CysLT2. Furthermore, we evaluated the link between these receptors and eosinophilic inflammation and we observed that both CysLT1 and CysLT2 correlated with markers of eosinophil activation like IL-5Rα, ECP and the number of activated eosinophils. The data obtained are in line with previous results showing that eosinophils are one of the most important sources of these receptors in inflamed upper airways [20, 21]; and that CysLT1 maybe involved in several stages of eosinophil differentiation, recruitment and maturation [2224]. In other hand, we did not found any changes in BLT receptors expression between controls and disease groups. These findings correspond with previous studies performed in aspirin intolerant nasal polyp patients [25] and with perennial allergic rhinitis [26]. However are in contrast with other reports showing increased levels of LTB4 and BLT receptors in allergic versus non-allergic nasal polyp patients [10]. Accordingly, there are no clear evidences about the role of these molecules in chronic rhinosinusitis and nasal polyposis and following our results, we question its role in these diseases.

As well as leukotrienes, prostaglandins and especially PGE2 play an important role in the regulation of the inflammatory process observed in chronic rhinosinusitis patients [27]. Little is known about the function and distribution of these receptors in airways and there are almost no studies reporting the action or regulation of these receptors in upper airway tissue. We show with this work that mRNA profile of prostanoid E receptors differs between chronic rhinosinusitis with and without polyps, again being different from healthy controls. We also observed that EP2 and EP4 receptors are up-regulated in chronic rhinosinusitis and nasal polyp tissue compared to control subjects; however, EP1 and EP3 transcripts were statistically decreased in the nasal polyp patients.

Figure 5

Prostanoid E receptors in chronic rhinosinusitistissue. Representative photomicrography (original magnification 40 ×) of chronic rhinosinusitis/nasal polyp specimens immunostained for EP1, EP2, EP3 and EP4 receptors in inflammatory cells, epithelium, glands and blood vessels.

It has been reported, that action of agonists of EP1, EP4 and of a variant of EP3 is mediated by increase of intracellular cAMP [28, 29]. In inflammatory cells, this phenomenon is associated with an inhibition of effector's cell functions such as activation, or response to certain stimulus [28, 29]. Accordingly, we can assume that down-regulation of these receptors may be related to an increase of functionality or maybe susceptibility of inflammatory cells to pro-inflammatory stimulus like IL-5 and leukotrienes contributing to the chronic inflammation observed in chronic rhinosinusitis and even more in nasal polyposis. However, and in contrast with the previous statement, interaction of PGE2 with EP1 and EP3 variants is translated in an increase of intracellular calcium, which can results in an induction of immune cell activation [29]. This process is of great importance in chronic rhinosinusitis/nasal polyposis because increase of intracellular calcium may induce the activation of cytosolic phospholipase A2 leading to the production of leukotrienes and other pro-inflammatory lipid mediators again contributing to the chronic inflammatory process observed in these diseases. However, this is in contradiction with our results where EP1 and EP3 are down- regulated in the disease groups.

Furthermore, an in vitro study performed on inflammatory cells demonstrated that eosinophils express high levels of EP2 and EP4 mRNA in comparison with EP1 and EP3, which were almost not present in these cells and that deficiency of PGE2 production may up-regulate the expression of EP2 and EP4 molecules [30]. This is on line with our findings however, mRNA levels of EP2 and EP4 receptors did not correlate with eosinophil number or eosinophil activation markers but it was increased in the disease groups compared to controls. In addition, PGE2 was down-regulated in chronic rhinosinusitis/nasal polyp tissue compared to chronic rhinosinusitis and normal nasal mucosa and the levels of this eicosanoid inversely correlated to eosinophilic inflammation. Analysing closely these results one may suggest that although synthesis of PGE2 may be related to eosinophil activation, regulation of its receptors at least at mRNA levels depends of mechanisms involving other cellular sources as showed recently by Ying and col. [15]. In addition, the lack of correlation and the similar mRNA profile of these receptors between the disease groups also suggest that functionality of these receptors may greatly depend of post-transcriptional regulation mechanisms. Here we were not able to analyze the protein expression of these molecules to confirm our PCR results but studies performed in nasal polyp patients partially support this hypothesis [15].

Conclusion

mRNA pattern of eicosanoid receptors is different between chronic rhinosinusitis and chronic rhinosinusitis/nasal polyp patients and compared to healthy subjects. CyLTs receptors are up-regulated in nasal polyp tissue and correlate with eosinophilic inflammation supporting previous results. Eicosanoid receptors mRNA pattern observed in our patient's groups suggest that down-regulation of EP1 and EP3 in the nasal polyp tissue and up-regulation EP2 and EP4 in both chronic rhinosinusitis groups may play a role in the development of the diseases and their regulation do not directly depend of eosinophil activation. Furthermore, these results also suggest the importance of post-transcriptional events in the regulation of receptor functionality involving other inflammatory multiple cellular sources. This is a descriptive preliminary study, which opens the door to more specific experiments including protein regulation, and functional studies that will reveal more information about the role of these receptors in chronic sinuses diseases.

Abbreviations

BLT1

leukotriene B4 receptor 1

BLT2

leukotriene B4 receptor 2

CRS: 

chronic rhinosinusitis

CRS-NP: 

chronic rhinosinusitis/nasal polyp

CysLTs: 

cysteinyl leukotrienes

CysLT1

cysteinyl leukotriene receptor 1

CysLT2

cysteinyl leukotriene receptor 2

EG2

eosinophil granulocyte

EP1

prostanoid receptor 1

EP2

prostanoid receptor 2

EP3

prostanoid receptor 3

EP4

prostanoid receptor 4

Sol-IL5Rα: 

soluble interleukin -5 receptor alpha

LTC4/D4/E4

leukotriene C4/D4/E4

LTB4

leukotriene B4

PGE2

prostaglandin E2

Declarations

Acknowledgements

This work has been partially supported by the grant: BOF 011D02903 granted to Claudina A. Pérez-Novo by the University of Ghent, Belgium.

Authors’ Affiliations

(1)
Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital

References

  1. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, Serhan CN, Shimizu T, Yokomizo T: International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003, 55:195–227.View ArticlePubMedGoogle Scholar
  2. Steinke JW, Borish L: Leukotriene receptors in rhinitis and sinusitis. Curr Allergy Asthma Rep 2004, 4:217–223.View ArticlePubMedGoogle Scholar
  3. Shirasaki H, Kanaizumi E, Watanabe K, Matsui T, Sato J, Narita S, Rautiainen M, Himi T: Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002, 32:1007–1012.View ArticlePubMedGoogle Scholar
  4. Figueroa DJ, Borish L, Baramki D, Philip G, Austin CP, Evans J: Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003, 33:1380–1388.View ArticlePubMedGoogle Scholar
  5. Lee KS, Kim SR, Park HS, Jin GY, Lee YC: Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 2004, 114:1093–1099.View ArticlePubMedGoogle Scholar
  6. Corrigan C, Mallett K, Ying S, Roberts D, Parikh A, Scadding G, Lee T: Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005, 115:316–322.View ArticlePubMedGoogle Scholar
  7. Tryselius Y, Nilsson NE, Kotarsky K, Olde B, Owman C: Cloning characterization of cDNA encoding a novel human leukotriene B(4) receptor. Biochem Biophys Res Commun 2000, 274:377–382.View ArticlePubMedGoogle Scholar
  8. Kamohara M, Takasaki J, Matsumoto M, Saito T, Ohishi T, Ishii H, Furuichi K: Molecular cloning and characterization of another leukotriene B4 receptor. J Biol Chem 2000, 275:27000–27004.PubMedGoogle Scholar
  9. Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B 4 . Eur Respir J 2000, 15:274–280.View ArticlePubMedGoogle Scholar
  10. Pinto S, Gallo O, Polli G, Boccuzzi S, Paniccia R, Brunelli T, Abbate R: Cyclooxygenase and lipoxygenase metabolite generation in nasal polyps. Prostaglandins Leukot Essent Fatty Acids 1997, 57:533–537.View ArticlePubMedGoogle Scholar
  11. Tager AM, Luster AD: BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 2003, 69:123–134.View ArticlePubMedGoogle Scholar
  12. Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147–166.View ArticlePubMedGoogle Scholar
  13. Sheller JR, Mitchell D, Meyrick B, Oates J, Breyer R: EP(2) receptor mediates bronchodilation by PGE (2) in mice. J Appl Physiol 2000, 88:2214–2218.PubMedGoogle Scholar
  14. Fortner CN, Breyer RM, Paul RJ: EP2 receptors mediate airway relaxation to substance P, ATP, and PGE 2 . Am J Physiol Lung Cell Mol Physiol 2001, 281:469–474.Google Scholar
  15. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH: Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells. J Allergy Clin Immunol 2006, 117:312–318.View ArticlePubMedGoogle Scholar
  16. Pérez C, Vandesompele J, Vandenbroucke I, Holtappels G, Speleman F, Gevaert P, Van Cauwenberge P, Bachert C: Quantitative real time polymerase chain reaction for measurement of human interleukin-5 receptor alpha spliced isoforms mRNA. BMC Biotechnol 2003, 3:1–17.View ArticleGoogle Scholar
  17. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000, 132:365–386.PubMedGoogle Scholar
  18. Livak KJ, Schmitteng TD: Analysis of relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 - ΔΔ C T Method. Methods 2001, 25:402–408.View ArticlePubMedGoogle Scholar
  19. Gevaert P, Bachert C, Holtappels G, Novo CP, Van der Heyden J, Fransen L, Depraetere S, Walter H, van Cauwenberge P, Tavernier J: Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy 2003, 58:371–379.View ArticlePubMedGoogle Scholar
  20. Pérez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C: Prostaglandin, Leukotriene and lipoxin balance in chronic Rhinosinusitis with and without nasal polyposis. Journal of Allergy and Clinical Immunology 2005, 115:1189–96.View ArticlePubMedGoogle Scholar
  21. Figueroa DJ, Borish L, Baramki D, Philip G, Austin CP, Evans JF: Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin Exp Allergy 2003, 33:1380–1388.View ArticlePubMedGoogle Scholar
  22. Fregonese L, Silvestri M, Sabatini F, Rossi GA: Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002, 32:745–750.View ArticlePubMedGoogle Scholar
  23. Saito H, Morikawa H, Howie K, Crawford L, Baatjes AJ, Denburg E, Cyr MM, Denburg JA: Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology 2004, 113:246–252.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Nagata M, Saito K, Tsuchiya K, Sakamoto Y: Leukotriene D 4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002, 109:676–680.View ArticlePubMedGoogle Scholar
  25. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH: Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002, 347:1493–1499.View ArticlePubMedGoogle Scholar
  26. Shahab R, Phillips DE, Jones AS: Prostaglandins, leukotrienes and perennial rhinitis. J Laryngol Otol 2004, 118:500–507.View ArticlePubMedGoogle Scholar
  27. Tilley SL, Coffman TM, Koller BH: Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108:15–23.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Peacock CD, Misso NL, Watkins DN, Thompson PJ: PGE 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Immunol 1999, 104:153–162.View ArticlePubMedGoogle Scholar
  29. Gerlo S, Verdood P, Gellersen B, Hooghe-Peters EL, Kooijman R: Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium-and cyclic adenosine 5'-monophosphate-mediated signaling pathways. J Immunol 2004, 173:5952–5962.View ArticlePubMedGoogle Scholar
  30. Mita H, Hasegawa M, Higashi N, Akiyama K: Characterization of PGE 2 receptor subtypes in human eosinophils. J Allergy Clin Immunol 2002, 110:457–459.View ArticlePubMedGoogle Scholar

Copyright

© Pérez-Novo et al. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement